Entero Therapeutics, Inc.
ENTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $29 | $106 | $537 |
| Gross Profit | $0 | -$29 | -$106 | -$537 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $5,033 | $691 | $38,320 |
| G&A Expenses | $15 | $10,738 | $11,987 | $18,385 |
| SG&A Expenses | $15 | $10,738 | $11,987 | $18,385 |
| Sales & Mktg Exp. | $156 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $529 |
| Operating Expenses | $16 | $15,771 | $12,678 | $56,705 |
| Operating Income | -$16 | -$15,771 | -$12,678 | -$59,057 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$24 | -$1,952 | -$1,833 |
| Pre-Tax Income | -$16 | -$15,795 | -$14,630 | -$58,538 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$18,059 | -$15,795 | -$14,630 | -$58,538 |
| % Margin | – | – | – | – |
| EPS | -3.88 | -46.96 | -407.37 | -27,544.98 |
| % Growth | 91.7% | 88.5% | 98.5% | – |
| EPS Diluted | -5.26 | -46.96 | -407.37 | -27,544.98 |
| Weighted Avg Shares Out | 4,653 | 336 | 36 | 2 |
| Weighted Avg Shares Out Dil | 3,435 | 336 | 36 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $8 | $1 |
| Interest Expense | $0 | $22 | $16 | $11 |
| Depreciation & Amortization | $49 | $29 | $29 | $542 |
| EBITDA | $33 | -$15,743 | -$14,584 | -$57,989 |
| % Margin | – | – | – | – |